Literature DB >> 29337802

Mesenchymal Stromal Cell Therapy: Does the Source Matter?

Sailaja Ghanta1, Min-Young Kwon, Ivan O Rosas, Xiaoli Liu, Mark A Perrella.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29337802      PMCID： PMC5819753          DOI： 10.1097/CCM.0000000000002894

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  24 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  Mesenchymal Stromal Cells Deficient in Autophagy Proteins Are Susceptible to Oxidative Injury and Mitochondrial Dysfunction.

Authors:  Sailaja Ghanta; Konstantin Tsoyi; Xiaoli Liu; Kiichi Nakahira; Bonna Ith; Anna A Coronata; Laura E Fredenburgh; Joshua A Englert; Claude A Piantadosi; Augustine M K Choi; Mark A Perrella
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914

3.  The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties.

Authors:  Gordana Raicevic; Mehdi Najar; Basile Stamatopoulos; Cecile De Bruyn; Nathalie Meuleman; Dominique Bron; Michel Toungouz; Laurence Lagneaux
Journal:  Cell Immunol       Date:  2011-05-30       Impact factor: 4.868

Review 4.  Marrow stromal cells as stem cells for nonhematopoietic tissues.

Authors:  D J Prockop
Journal:  Science       Date:  1997-04-04       Impact factor: 47.728

Review 5.  Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy.

Authors:  Stella Kourembanas
Journal:  Annu Rev Physiol       Date:  2014-09-25       Impact factor: 19.318

6.  Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia.

Authors:  So Yoon Ahn; Yun Sil Chang; Ji Hye Kim; Se In Sung; Won Soon Park
Journal:  J Pediatr       Date:  2017-03-21       Impact factor: 4.406

7.  Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.

Authors:  Marilyn K Glassberg; Julia Minkiewicz; Rebecca L Toonkel; Emmanuelle S Simonet; Gustavo A Rubio; Darcy DiFede; Shirin Shafazand; Aisha Khan; Marietsy V Pujol; Vincent F LaRussa; Lisa H Lancaster; Glenn D Rosen; Joel Fishman; Yolanda N Mageto; Adam Mendizabal; Joshua M Hare
Journal:  Chest       Date:  2016-11-24       Impact factor: 9.410

Review 8.  Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis.

Authors:  James Walter; Lorraine B Ware; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-10-28       Impact factor: 30.700

9.  Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils.

Authors:  Sean R R Hall; Konstantin Tsoyi; Bonna Ith; Robert F Padera; James A Lederer; Zhihong Wang; Xiaoli Liu; Mark A Perrella
Journal:  Stem Cells       Date:  2013-02       Impact factor: 6.277

10.  Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.

Authors:  Guoping Zheng; Lanfang Huang; Haijiang Tong; Qiang Shu; Yaoqin Hu; Menghua Ge; Keqin Deng; Liuya Zhang; Bin Zou; Baoli Cheng; Jianguo Xu
Journal:  Respir Res       Date:  2014-04-04
View more
  1 in total

Review 1.  Mesenchymal Stem Cells Transplantation in Intracerebral Hemorrhage: Application and Challenges.

Authors:  Yu-Hua Gong; Shi-Lei Hao; Bo-Chu Wang
Journal:  Front Cell Neurosci       Date:  2021-03-24       Impact factor: 5.505
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.